Stay updated on STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest updates to the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedThe website has updated its contact information and personnel details, including the addition of new contacts and a revision update from v2.13.3 to v2.14.0.SummaryDifference5%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedDifference0.3%
- Check32 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.4%
- Check39 days agoChange DetectedThe website has updated the contact details section for the study, clarifying that it now provides information for those who can answer questions about joining the study, along with a reference to the Contacts and Locations section.SummaryDifference2%
- Check53 days agoChange DetectedSeveral key resources related to ovarian cancer and treatment options have been removed, including links to MedlinePlus and NIH, which may impact access to important genetic and disease information.SummaryDifference4%
- Check68 days agoChange DetectedThe website has added new recruiting information for a study on ovarian cancer, including multiple principal investigators and their contact details, while removing outdated status and revision information.SummaryDifference9%
Stay in the know with updates to STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the STRO-002 Combo with Bevacizumab in Ovarian Cancer Clinical Trial page.